, which is forward-looking in the third-generation sequencing technology, has welcomed a new helper at the hardware level.
Recently, Pacific Biosciences (PacBio), a third-generation sequencer research and development and manufacturing company, launched the new Revio long read and long sequencing system, which is a historic improvement compared to the past - not only achieving higher HiFi data throughput and stronger computing power, but also greatly reducing costs. As PacBio's major global partner, Berry Gene is also the official partner of Revio's global launch. It will be the first to introduce and use the sequencer to provide support for third-generation clinical applications and scientific research.
Revio: Super chip, ultra-high throughput, super computing power, cost-effective
As the new main model of PacBio, the Revio data is very eye-catching. Whether in terms of chip, throughput, computing power or cost, various historic breakthroughs are full of expectations. PacBio said that Revio can apply HiFi sequencing to large-scale research in human genetics, cancer research, agricultural genomics and other aspects.
According to reports, Revio can provide the ability to sequence up to 1,300 human whole genomes at a 30-fold coverage rate each year, while the cost of each sequencing is less than $1,000, reducing HiFi-based human whole genome sequencing to less than $1,000. While
is at the cost, it is also a comprehensive improvement in performance. Revio uses the new SMRT Cell chip, which is three times the density of the existing (8M) and has 25 million ZMW (zero-mode waveguide holes) on it. Revio can parallel up to 4 SMRT cells simultaneously, providing up to 100 million ZMW (zero-mode waveguide holes) for single-molecule real-time sequencing. Combined with significant advances in computing, Revio will provide shorter runtime and increase HiFi data throughput by 15 times. That is, the advent of Revio allows all of this to be achieved at a larger throughput scale with accurate raw long read lengths, uniform sequencing coverage, variation detection accuracy and assembly integrity, and accurate DNA methylation detection.
In addition, Revio uses an advanced NVIDIA GPU system, which has a 20-fold increase in computing power compared to Sequel IIe. Consumables use was reduced in half and major improvements were made in workflow and convenience. It is worth mentioning that Revio also integrates deep learning methods developed with Google Health into the sequencer to improve HiFi production and sequencing accuracy.
Berry Gene: jointly developed a three-generation desktop sequencer, and implemented a number of third-generation products
It is understood that Berry Gene has long been laying out and established a first-mover advantage in the field of third-generation sequencing. It not only leads a number of major scientific research, but also implemented a number of products. The first introduction and use of Revio will further accelerate the company's exploration of third-generation sequencing.
In fact, as early as 2019, Berry Gene reached a long-term cooperation with PacBio. The three-generation sequencing platform Sequel® II CNDx, jointly developed by the two parties, has now entered the clinical trial stage of medical device registration. In January this year, the two parties began to jointly develop a desktop sequencer based on the third-generation sequencing technology. This sequencer is small and convenient, flexible to deploy, lowers the threshold for use, and has extremely high cost-effectiveness. This joint research and development will meet multi-level needs and advance the service of Chinese clinical practice to a deeper stage.
At present, there are 21 Sequel II/IIe sequencers for Berry Gene. On this basis, the company provides high-quality sequencing services to the majority of genomics and transcriptomics researchers. It has completed 3,500+ third-generation sequencing projects and completed more than 10,000 samples in total. The number of Cells under PacBio sequencing has exceeded 8,000, and the output of PacBio HiFi data per Cell has exceeded 45G!
is based on the third-generation sequencer with excellent performance. Under the guidance of clinical research results, Berry Gene continues to expand its application scenarios, and has implemented three-generation thalassemia, three-generation CAH (congenital adrenal hyperplasia), three-generation SMA (spinal muscular atrophy), and three-generation FXS (fragile X syndrome) products, setting the sword for the "four evil people".
In the future, with the introduction and use of the Revio platform, Berry Gene will challenge more complex gene mutation diseases, striving to achieve accurate "one-click solution" in the detection of single-gene and whole disease types!
text/Zhou Bin
